http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고지방식이 비만마우스 모델에서 파키스탄산 및 중국산 마황으로 조성된 강지환(降脂丸)의 체중감량 효과 비교
김병출,석화준,유재상,구자룡,윤기현,조주흠,장두현,정양삼,김종훈,안예지,우상이,윤미소,신순식,Kim, Byeong Chul,Seok, Hoa Jun,Yoo, Jae Sang,Ku, Ja Ryong,Yoon, Ki Hyeon,Jo, Ju Heum,Jang, Du Hyon,Jung, Yang Sam,Kim, Jong Hoon,Ahn, Ye Ji,Woo, San 대한한의학방제학회 2014 大韓韓醫學方劑學會誌 Vol.22 No.2
Objectives : This study investigated the improvement effects of Pakistani (DF-a) and Chinese Ephedra herba-containing Gangjihwan (DF-b) on obesity in a high fat diet-fed obese mouse model. Methods : Eight-week-old C57BL/6N mice were divided into four groups: a normal lean group given a standard diet, an obese control group given a high fat diet, and DF-a and DF-b groups given a high fat diet with DF-a (80 mg/kg), and DF-b (80 mg/kg), respectively. After 8 weeks of treatment, body weight gain, feeding efficiency ratio, blood lipid markers, fat weight and histology were examined. Results : 1. Body weight gain and fat mass were significantly decreased in DF-a and DF-b groups compared with control. The extent of decreases was eminent in DF-a group. 2. Feeding efficiency ratio and circulating leptin concentration were significantly decreased in DF-a and DF-b groups compared with control, whereas circulating adiponectin concentration was increased in DF-a and DF-b groups compared with control. 3. Consistent with their effects on body weight gain and fat mass, circulating concentrations of triglyceride, glucose and insulin were decreased in DF-a and DF-b groups compared with control. 4. The size of adipocytes were decreased by DF-a and DF-b compared with control, whereas the adipocyte number per unit area was increased by them, suggesting that DF-a and DF-b decreased the number of large adipocytes. 5. Consistent with their effects on body weight gain, liver fibrosis was reduced in DF-a and DF-b groups compared with control. Conclusions : In conclusion, these results suggest that DF-a and DF-b not only decrease feeding efficiency ratio, plasma leptin concentration, and blood anti-obesity biomarkers, but also reduce fat mass, contributing to the improvement of obesity. DF-a and DF-b also inhibit liver fibrosis. In addition, these effects were similar between Pakistani Ephedra herba and Chinese Ephedra herba-containing Gangjihwan.
고지방식이 수컷 micro-pig에서 경신강지환(經身降脂丸) (GGEx)의 고지혈증 개선효과
양유인,정양삼,이희영,이상달,김병출,김종훈,석화준,유재상,윤기현,조주흠,김훈,김경철,신순식,Yang, Yoo-In,Jung, Yang-Sam,Lee, Hee-Young,Rhee, Sang-Dal,Kim, Byoung-Chul,Kim, Jong-Hoon,Seok, Hoa-Jun,Yoo, Jae-Sang,Yoon, Ki-Hyeon,Jo, Ju-Heum,Kim, 대한한의학방제학회 2006 大韓韓醫學方劑學會誌 Vol.14 No.2
Objectives : We evaluated anti-hyperlipidemia effect of Gyeongshinganjeehwan (GGEx) in high fat induced obese male micro-pigs. Methods : 7 month-old micro-pigs are fed with normal (n = 3) or high fat diet (n = 18) for 12 weeks. The pig revealed obesity in high fat diet were divided into 2 groups (n = 5 each) and vehicle (OMP) and Gyeongshingangjeehwan (GGEx, 616.7 mg/kg/day) were administrated for 1 month. We monitored the changes in body weight and measured plasma cholesterol, triglyceride, free fatty acid, GOT and, GPT after 1 month. The visceral fat were measured with computerized tomography and weights of various organs were measured after sacrifice. Results : 1. GGEx group had significantly reduced body weight gain than obese control group in statistics. 2. GGEx group didn't significantly differ from obese control group in blood total cholesterol, blood LDL-cholesterol, blood triglyceride. but it's data were similar to normal control group. 3. GGEx group had prominantly reduced visceral fat than obese control group in computerized tomography. 4. Blood GOT and GPT didn't differ from between groups. The organ weight were not significant different. And it is normal in size and colour of visceral organs. Conclusions : It is concluded that GGEx has anti-hyperlipidemia effect by improving visceral fat and access to security.
고지방식이 마우스 비만모델에서 인제청금단에 의한 체중감량과 혈중 지질대사의 개선효과
양승엽,이희영,이혜림,김병출,박순일,안예지,오재호,임혜숙,윤미정,신순식,Yang, Seung-Yeob,Lee, Hee-Young,Lee, Hye-Rim,Kim, Byoung-Chul,Park, Soon-Ill,Ahn, Ye-Ji,Oh, Jae-Ho,Lim, Hye-Sook,Yoon, Mi-Chung,Shin, Soon-Shik 대한한의학방제학회 2012 大韓韓醫學方劑學會誌 Vol.20 No.1
Objectives : We investigated the effects of Ingecheonggeumdan(ICD) on body weight and examined whether blood lipid levels and visceral fat are inhibited by it in high fat diet-fed obese male mice. Methods : 8 weeks old, high fat diet-fed obese male mice were divided into 6 groups: C57BL/6N normal, control, ICD-1(150mg/kg), ICD-2(300mg/kg), ICD-3(600mg/kg) and orlistat(10mg/kg). After mice were treated with ICD and orlistat for 8 weeks, we measured body weight gain, food intake, feeding efficiency ratio, fat weight, plasma leptin and lipid levels. We also performed histological analysis for liver and fat on the mice. Results : Compared with controls, ICD and orlistat-treated mice had lower body weight gain and adipose tissue weight, the magnitudes of which were prominent in ICD-3. Compared with controls, ICD and orlistat-treated mice had lower blood leptin levels, the magnitude of which was prominent in ICD-3. Compared with controls, ICD and orlistat-treated mice had higher blood HDL-cholesterol and lower blood plasma LDL-cholesterol, free fatty acid and triglyceride levels, the magnitudes of which were prominent in ICD-3. Blood plasma AST and ALT concentrations were not changed by ICD and orlistat, indicating ICD and orlistat do not show any toxic effects. Consistent with their effects on body weight gain, the size of adipocytes and hepatic lipid accumulation were significantly decreased by ICD and orlistat. Conclusions : These results demonstrate that ICD and orlistat effectively reduce body weight gain, blood plasma LDL-cholesterol, free fatty acid and triglyceride levels and improves abdominal fat, the magnitudes of which were prominent in ICD-3.
논문 철회 : 고지방식이 비만마우스 모델에서 파키스탄산 및 중국산 마황으로 조성된 강지환(降脂丸)의 비알콜성 지방간질환 개선효과 비교
조주흠,장두현,정양삼,김종훈,김병출,석화준,유재상,구자룡,윤기현,노종성,안예지,이원경,윤미정,신순식,Jo, Ju-Heum,Jang, Du-Hyeon,Jeong, Yang-Sam,Kim, Jong-Hun,Kim, Byeong-Chul,Seok, Hwa-Jun,Yu, Jae-Sang,Gu, Ja-Ryong,Yun, Gi-Hyeon,No, Jong-Seong,A 대한한의학방제학회 2021 大韓韓醫學方劑學會誌 Vol.29 No.4
논문 철회 : 고지방식이 비만마우스 모델에서 강지환(降脂丸)과 강지환(降脂丸)+가미소체환(加味消滯丸)의 비알콜성 지방간질환 개선효과 비교
장두현,정양삼,김종훈,김병출,석화준,유재상,구자룡,윤기현,조주흠,이혜림,노종성,윤호영,윤미정,신순식,Jang, Du-Hyeon,Jeong, Yang-Sam,Kim, Jong-Hun,Kim, Byeong-Chul,Seok, Hwa-Jun,Yu, Jae-Sang,Gu, Ja-Ryong,Yun, Gi-Hyeon,Jo, Ju-Heum,Lee, Hye-Rim,No, 대한한의학방제학회 2021 大韓韓醫學方劑學會誌 Vol.29 No.4
고지방식이 비만마우스 모델에서 파키스탄산 및 중국산 마황으로 조성된 강지환(降脂丸)의 비알콜성 지방간질환 개선효과 비교
조주흠,장두현,정양삼,김종훈,김병출,석화준,유재상,구자룡,윤기현,노종성,안예지,이원경,윤미정,신순식,Jo, Ju Heum,Jang, Du Hyon,Jung, Yang Sam,Kim, Jong Hoon,Kim, Byeong Chul,Seok, Hoa Jun,Yoo, Jae Sang,Ku, Ja Ryong,Yoon, Ki Hyeon,Roh, Jong Seong 대한한의학방제학회 2014 大韓韓醫學方劑學會誌 Vol.22 No.1
Objectives : This study investigated the improvement effects of Pakistani (DF-a) and Chinese Ephedra herba-containing Gangjihwan (DF-b) on nonalcoholic fatty liver disease in a high fat diet-induced obese mouse model. Methods : Eight-week-old C57BL/6N mice were divided into five groups: a normal lean group given a standard diet, an obese control group given a high fat diet, and atorvastatin, DF-a, and DF-b groups given a high fat diet with atorvastatin (10 mg/kg), DF-a (80 mg/kg), and DF-b (80 mg/kg), respectively. After 8 weeks of treatment, body weight gain, blood lipid markers, ALT concentrations, liver weight and histology were examined. Results : 1. Body weight gain was significantly decreased in DF-a, DF-b, and atorvastatin groups compared with control. The extent of decreases was eminent in DF-a group. 2. Circulating concentrations of total cholesterol and LDL-cholesterol were significantly decreased in DF-a, DF-b, and atorvastatin groups compared with control. The decreases were most effective in atorvastatin group. 3. Liver weights were decreased in DF-a, DF-b, and atorvastatin groups compared with control. In particular, liver weight was significantly reduced in DF-b group. 4. Hepatic lipid accumulation was significantly decreased in DF-a, DF-b, and atorvastatin groups compared with control, and the magnitude of which was most effective in DF-b group. 5. Circulating ALT concentrations were decreased in DF-a, DF-b, and atorvastatin groups compared with control, but ALS levels were significantly reduced only in DF-b group. Conclusions : In conclusion, these results suggest that DF-a and DF-b decrease body weight gain, improve blood lipid metabolism, and reduce liver weight and hepatic lipid accumulation, contributing to the improvement of nonalcoholic fatty liver disease. In addition, these effects were similar between Pakistani and Chinese Ephedra herba-containing Gangjihwan.
고지방식이 비만마우스 모델에서 강지환(降脂丸)과 강지환(降脂丸)+가미소체환(加味消滯丸)의 비알콜성 지방간질환 개선효과 비교
장두현,정양삼,김종훈,김병출,석화준,유재상,구자룡,윤기현,조주흠,이혜림,노종성,윤호영,윤미정,신순식,Jang, Du Hyon,Jung, Yang Sam,Kim, Jong Hoon,Kim, Byeong Chul,Seok, Hoa Jun,Yoo, Jae Sang,Ku, Ja Ryong,Yoon, Ki Hyeon,Jo, Ju Heum,Lee, Hye Rim,Ro 대한한의학방제학회 2014 大韓韓醫學方劑學會誌 Vol.22 No.1
Objectives : This study investigated the improvement effects of Gangjihwan (DF) and combination of Gangjihwan and Gamisochehwan (GSH) on nonalcoholic fatty liver disease in a high fat diet-induced obese mouse model. Methods : Eight-week-old C57BL/6N mice were divided into five groups: a normal lean group given a standard diet, an obese control group given a high fat diet, and atorvastatin, DF, and DF+GSH groups given a high fat diet with atorvastatin (10 mg/kg), DF (40 mg/kg), and DF+GSH (80 mg/kg), respectively. After 8 weeks of treatment, body weight gain, blood lipid markers, ALT concentrations, liver weight and histology were examined. Results : 1. Body weight gain was significantly decreased in DF, DF+GSH and atorvastatin groups compared with control. The extent of decreases was eminent in DF+GSH group. 2. Circulating concentrations of total cholesterol, HDL-cholesterol and LDL-cholesterol were decreased in DF, DF+GSH and atorvastatin groups compared with control. The decreases were significant in DF+GSH and atorvastatin groups. 3. Liver weights were decreased in DF, DF+GSH and atorvastatin groups compared with control. In particular, liver weight was significantly reduced only in DF+GSH group. 4. Hepatic lipid accumulation was significantly decreased in DF, DF+GSH and atorvastatin groups compared with control, and the magnitude of which was more effective in DF+GSH group than in DF-only group. 5. Circulating ALT concentrations were decreased in DF, DF+GSH and atorvastatin compared with control, but ALS levels were significantly reduced only in DF+GSH group. Conclusions : In conclusion, these results suggest that DF decreases body weight gain, improves blood lipid metabolism, and reduces liver weight and hepatic lipid accumulation, contributing to the improvement of nonalcoholic fatty liver disease. In addition, these effects were more effective in DF+GSH combination group than in DF-only group.
고지방식이 비만마우스 모델에서 파키스탄산 및 중국산 마황으로 조성된 강지환(降脂丸)-1,2,3,4과 降脂丸-1+가미소체환(加味消滯丸)의 비알콜성 지방간질환 개선효과 비교
정양삼 ( Yang Sam Jung ),김종훈 ( Jong Hoon Kim ),김병출 ( Byeong Chul Kim ),석화준 ( Hoa Jun Seok ),유재상 ( Jae Sang Yoo ),구자룡 ( Ja Ryong Ku ),윤기현 ( Ki Hyeon Yoon ),조주흠 ( Ju Heum Jo ),장두현 ( Du Hyon Jang ),윤호영 ( Ho 대한본초학회 2014 大韓本草學會誌 Vol.29 No.6
Objectives : This study investigated the improvement effects of Gangjihwan-1,2,3,4 (DF-1,2,3,4) and combination of DF-1 and Gamisochehwan (GSH) on nonalcoholic fatty liver disease in a high fat diet-fed obese mouse model. Methods : Eight-week-old C57BL/6N mice were divided into eight groups: a normal lean group given a standard diet, an obese control group given a high fat diet, and atorvastatin, DF-1,2,3,4, and DF-1+GSH groups given a high fat diet with atorvastatin (10 mg/kg), DF-1,2,3,4 (40, 80, 160, 80 mg/kg), and DF-1+GSH (80 mg/kg), respectively. After 8 weeks of treatment, body weight gain, blood lipid markers, ALT concentrations, liver weight and histology were examined. Results : Body weight gain was significantly decreased in DF-1,2,3,,4, DF-1+GSH and atorvastatin groups compared with control. The extent of decreases was eminent in DF-1+GSH group. Circulating concentrations of total cholesterol and LDL-cholesterol were significantly decreased in DF-2, DF-4, DF-1+GSH and atorvastatin groups compared with control. Liver weights, hepatic lipid accumulation and hepatic fibrosis were significantly decreased in DF-1,2,3,4, DF-1+GSH and atorvastatin groups compared with control, and the magnitude of which was more effective in DF-1+GSH group than in DF-only group. Circulating ALT concentrations were significantly decreased only in DF-4 and DF-1+GSH groups. Conclusions : In conclusion, these results suggest that DF decreases body weight gain, improves blood lipid metabolism, and reduces liver weight and hepatic lipid accumulation and hepatic fibrosis, contributing to the improvement of nonalcoholic fatty liver disease. In addition, these effects were more effective in DF-1+GSH combination group than in DF-only group.